A similar conclusion was drawn by Baird and colleagues [139], who showed that CHRFAM7A expression was increased, and that CHRNA7 expression was decreased in Inflammatory Bowel Disease (IBD), thus suggesting that CHRFAM7A may be an unrecognized target for the development of therapeutics for IBD. This evidence concerns the gene CHRFAM7A and inflammatory bowel disease.